Heating Cold Prostate Tumors with PSMA-Targeted Alpha Therapy and Pembrolizumab
Abstract
Treatment of prostate cancer using immune checkpoint inhibition combined with androgen receptor signaling inhibitors results is ineffective in most. Other methods of treatment need to be studied to develop novel strategies to improve prognosis of these patients. We hypothesize that the combination of pembrolizumab plus androgen receptor signaling inhibitor plus 225Ac-J591 is safe. We also hypothesize that the addition of 225Ac-J591 to the backbone of pembrolizumab plus androgen receptor signaling inhibitor will lead to more responses compare to pembrolizumab plus androgen receptor signaling inhibitor alone and that we can identify subsets more or less likely to respond. In this project, we will utilize our prospective data and sample sets to: (i) compare the efficacy of the addition of PSMA-targeted alpha emitting radionuclide therapy to anti PD-1 and AR signaling inhibition versus pembrolizumab and AR signaling inhibition alone; and (ii) assess the optimal patient/tumor population for immune checkpoint inhibition with pembrolizumab with or without PSMA-targeted alpha emitting radionuclide therapy. This project will evaluate whether the combination of PSMA-based targeted radionuclide therapy using alpha emitting 225Ac with immune checkpoint inhibitor and androgen receptor signaling inhibitor will result in more accurate cancer cell targeting and more robust, systemic immune response to maximize their effects. The findings from this project may provide valuable information to help with uncovering cures for men with metastatic castration resistant prostate cancer.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2022
- Accession Number
- AD1206337
Entities
People
- Scott T Tagawa
Organizations
- Cornell University